Androgen deprivation therapy for prostate cancer: Current status and future prospects

Hiroshi Miyamoto, Edward M. Messing, Chawnshang Chang

Research output: Contribution to journalArticlepeer-review

249 Scopus citations


Androgens play a major role in promoting the development and progression of prostate cancer. As a result, androgen ablation or blockade of androgen action through the androgen receptor (AR) has been the cornerstone of treatment of advanced prostate cancer. Different strategies involving this hormonal therapy produce a significant clinical response in most of the patients, but most responders eventually lose dependency, resulting in mortality. Thus, whether hormonal therapy contributes to the improvement of overall survival rates, especially in patients with advanced prostate cancer, remains controversial. However, patients with advanced disease clearly have a benefit from androgen deprivation-based treatment for palliating their symptoms and for improving the quality of their lives. In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified.

Original languageEnglish (US)
Pages (from-to)332-353
Number of pages22
Issue number4
StatePublished - Dec 1 2004


  • Androgen receptor
  • Androgen receptor coregulator
  • Androgen-independent prostate cancer
  • Antiandrogen
  • Antiandrogen withdrawal syndrome

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Androgen deprivation therapy for prostate cancer: Current status and future prospects'. Together they form a unique fingerprint.

Cite this